# Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

> **NCT02483585** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 577 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02483585
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-20
- **Primary completion:** 2016-07-11
- **Final completion:** 2017-03-20
- **Target enrollment:** 577 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483585, "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02483585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*